Milk Exosomes. This project starts with the observation that mammalian mothers use exosomes in their milk to transfer large molecules (e.g., antibodies) from their baby’s gut into the blood. Because bovine antibodies cross-react with the human Fc receptor, cow exosomes can be used to transport therapeutic molecules from a patient’s gut to their blood. This potentially would enable a variety of molecules (chemotherapeutics, peptides, RNA) to be administered orally instead of via IV infusion. This would reduce the need for patients to travel to infusion centers and/or hospitals for treatment.
Endothelial Tightening. This project exploits the fact that gene delivery vehicles elicit an antiviral response when administered systemically, i.e., the body reacts as if it is being infected. As a mechanism of limiting the spread of infection, the body signals the vascular endothelium to limit particle uptake. However, we have observed that the immunosuppressed state of the tumor prevents this effect, thereby allowing particles to preferentially access the tumor while reducing accumulation in non-target tissues. We are currently characterizing this phenomenon and will utilize this to improve nanoparticle-mediated delivery to tumors.
Stimulating an Antitumor Response. It has been knows for decades that the administration of gene delivery vehicles stimulates a potent immune response that can be used to shrink tumors. While these effects are quite remarkable, the tumors ultimately grow back. This project focuses on combining this effect with antibiotics that target bacteria that live within the tumor to delay and potentially prevent cancer recurrence.
Lyophilization of mRNA Vaccines. The pandemic has brought mRNA technology to the forefront and the requirement that the vaccine be shipped and stored in the frozen state limits distribution within the U.S. and abroad. While our laboratory has conducted many studies with DNA, our most recent investigation into lyophilization and storage stability involves mRNA-lipid complexes. As part of this work, we are developing methods to quantitatively evaluate the degradation of mRNA.
Jamie Betker, Professional Research Assistant - Jamie has been working on various projects in lab for 12 years. She has been in many previous labs including University of Colorado, University of Washington, and Cornell University. She is primarily an experimentalist.
Catherine Nicholls, BS, Professional Research Assistant - Catherine received a Bachelor of Sciences (BS) degree in Neuroscience from Baylor University in 2019, and joined the Anchordoquy lab in March of 2020. While studying neuroscience, she fell in love with organic chemistry, pharmacology, and the pharmaceutical sciences. After graduating, she worked in clinical sleep research and volunteered in a behavioral neuroscience lab at CU Boulder. She wanted to move into bench- based and animal-based research, and soon after joined the Anchordoquy lab. Catherine looks forward to pursuing her PhD in Neuropharmacology in the coming years. She is currently working on using exosomes from cow milk for oral delivery of chemotherapeutics.
Madison Ricco - Madison is a PharmD candidate for the class of 2022 who has been working in Dr. Anchordoquy's lab since her first year at Anschutz. She has interest in oncology research and is pursuing a M.S. in Pharmaceutical Sciences on the PK/PD track at the Skaggs School of Pharmacy to supplement her clinical education.
Scott Tilden, Graduate Student - Scott is a Colorado native from Golden. He graduated from the University of Colorado Boulder with a BA in Biochemistry and a BA in Molecular Cellular Developmental Biology. After graduation, Scott worked at CU Boulder for four years in the Maier/Watkins Neuroscience Laboratory and the Hough Biochemical and Biophysical Laboratory. Scott started at Anschutz in fall 2018 and joined Dr. Anchordoquy’s lab in the spring of 2019. Scott’s main interest is investigating how to induce anti-viral responses to manipulate endothelial permeability and reduce off-target toxicity/accumulation of nanomedicines. He and Dr. Anchordoquy have also working closely with a local epilepsy research company to develop novel formulation of anticonvulsant pharmaceuticals to be used in clinical trials.
|Jasmina Redzic||University of Colorado|
|Tyson Smyth||Nektar Therapeutics|
|Max Kullberg||University of Alaska|
|Long Xu||Johnson and Johnson|
|Matt Fete||Chicago State University|
|Yvonne Lentz||Bristol Meyers Squibb|